摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

12-( 4-chlorophenyl)-5-methyl-3,4-dihydrobenzo[b]acridine-1,6,11(2H,5H,12H)-trione | 1548480-34-7

中文名称
——
中文别名
——
英文名称
12-( 4-chlorophenyl)-5-methyl-3,4-dihydrobenzo[b]acridine-1,6,11(2H,5H,12H)-trione
英文别名
12-(4-chlorophenyl)-5-methyl-3,4-dihydrobenzo[b]acridine-1,6,11(2H,5H,12H)-trione;12-(4-chlorophenyl)-5-methyl-2,3,4,12-tetrahydrobenzo[b]acridine-1,6,11-trione
12-( 4-chlorophenyl)-5-methyl-3,4-dihydrobenzo[b]acridine-1,6,11(2H,5H,12H)-trione化学式
CAS
1548480-34-7
化学式
C24H18ClNO3
mdl
——
分子量
403.865
InChiKey
KLVXAFARPRZWPP-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.1
  • 重原子数:
    29
  • 可旋转键数:
    1
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.21
  • 拓扑面积:
    54.4
  • 氢给体数:
    0
  • 氢受体数:
    4

反应信息

  • 作为产物:
    描述:
    12-(4-chlorophenyl)-3,4-dihydrobenzo[b]acridine-1,6,11(2H,5H,12H)-trione 、 碘甲烷potassium carbonate 作用下, 以 丙酮 为溶剂, 反应 72.0h, 以47%的产率得到12-( 4-chlorophenyl)-5-methyl-3,4-dihydrobenzo[b]acridine-1,6,11(2H,5H,12H)-trione
    参考文献:
    名称:
    [EN] FUSED QUINONIC COMPOUNDS
    [FR] COMPOSÉS QUINONIQUES FUSIONNÉS
    摘要:
    一个具有公式(I)的化合物,用于治疗疾病;一种包含所述公式(I)的融合醌化合物和至少一种药物可接受载体的组合物;以及一种调节Janus激酶-信号转导和转录激活因子(JAK-STAT)通路的方法。JAK和/或STAT通路的激活与多种疾病状态有关,如免疫性和炎症性疾病、包括癌症在内的过度增殖障碍以及骨髓增殖性疾病。
    公开号:
    WO2014016314A1
点击查看最新优质反应信息

文献信息

  • Fused quinonic compounds
    申请人:Centro Atlantico del Medicamento S.A (Ceamed, S.A)
    公开号:EP2690094A1
    公开(公告)日:2014-01-29
    A compound having the formula (I): for use in treating disease; a composition comprising said fused quinonic compound of formula (I) and at least one pharmaceutically acceptable carrier; as well as a method of modulating a Janus Kinase-Signal Transduction and Activators of Transcription (JAK-STAT) pathway. The activation of a JAK-STAT pathway is associated with several disease states such as immunological and inflammatory diseases, hyperproliferative disorders including cancer, and myeloproliferative diseases.
    具有公式(I)的化合物: 用于治疗疾病;包含所述公式(I)的融合醌类化合物和至少一种药物可接受的载体的组合物;以及一种调节Janus激酶-信号转导和转录激活因子(JAK-STAT)通路的方法。JAK-STAT通路的激活与多种疾病状态有关,如免疫性和炎症性疾病、包括癌症在内的过度增殖障碍以及骨髓增殖性疾病。
  • FUSED QUINONIC COMPOUNDS
    申请人:CENTRO ATLANTICO DEL MEDICAMENTO S.A (CEAMED, S.A.)
    公开号:US20150175585A1
    公开(公告)日:2015-06-25
    A compound having the formula (I): for use in treating a disease; a composition comprising said fused quinonic compound of formula (I) and at least one pharmaceutically acceptable carrier; as well as a method of modulating a Janus Kinase-Signal Transduction and Activators of Transcription (JAK-STAT) pathway. The activation of a JAK and/or STAT pathways are associated with several disease states such as immunological and inflammatory diseases, hyperproliferative disorders including cancer, and myeloproliferative diseases.
    一种具有公式(I)的化合物,用于治疗疾病;包含公式(I)的融合喹啉化合物和至少一种药用载体的组合物;以及一种调节Janus激酶-信号转导和转录激活因子(JAK-STAT)通路的方法。激活JAK和/或STAT通路与多种疾病状态相关,包括免疫和炎症性疾病、增生性疾病(包括癌症)和骨髓增生性疾病。
  • [EN] FUSED QUINONIC COMPOUNDS<br/>[FR] COMPOSÉS QUINONIQUES FUSIONNÉS
    申请人:CT ATLANTICO DEL MEDICAMENTO S A CEAMED S A
    公开号:WO2014016314A1
    公开(公告)日:2014-01-30
    A compound having the formula (I), for use in treating a disease; a composition comprising said fused quinonic compound of formula (I) and at least one pharmaceutically acceptable carrier; as well as a method of modulating a Janus Kinase-Signal Transduction and Activators of Transcription (JAK-STAT) pathway. The activation of a JAK and/or STAT pathways are associated with several disease states such as immunological and inflammatory diseases, hyperproliferative disorders including cancer, and myeloproliferative diseases.
    一个具有公式(I)的化合物,用于治疗疾病;一种包含所述公式(I)的融合醌化合物和至少一种药物可接受载体的组合物;以及一种调节Janus激酶-信号转导和转录激活因子(JAK-STAT)通路的方法。JAK和/或STAT通路的激活与多种疾病状态有关,如免疫性和炎症性疾病、包括癌症在内的过度增殖障碍以及骨髓增殖性疾病。
查看更多